Impact of Baseline PSA Level on Quality of Life Measures of General Health and Sexual Satisfaction/Drive in Men with BPH Treated with Finasteride or Placebo

The study examined the impact of baseline prostate-specific antigen (PSA) levels on quality of life measures, specifically general health and sexual satisfaction/drive, in men with benign prostatic hyperplasia (BPH) treated with either finasteride or a placebo. The research aimed to determine if initial PSA levels influenced the outcomes of these treatments. The findings suggested that baseline PSA levels did have an effect on the quality of life measures, with variations observed in general health and sexual satisfaction/drive between the finasteride and placebo groups. However, the document did not specify the number of participants involved in the study, which is crucial for assessing the strength of the findings.